D30M-1 -POSITIVE anaplastic large-cell lymphoma (ALCL) is a wehecognized clinicopathologic entity'-5 that has been integrated into recent lymphoma classificat i o n~. "~ Distinctive features of ALCL are sinus and paracortical infiltration of lymph nodes by polymorphic tumor cell^,'.^-^ frequent extranodal disease, especially skin? and characteristic chromosomal translocation t(2;5)(p23;q35).9.'0 ALCL cells consistently express the activation antigen CD30 (Kil),'.'' a newly recognized member of the tumor necrosis factor receptor (TNFR) ~uperfamily.'~"~ ALCL is usually responsive to aggressive chemotherapy and shows the same complete remission (CR) and overall survival rates as other varieties of large-cell lymphoma^?'^"^ Nevertheless, 30%
to 40% of patients eventually die of their disease. Therefore, alternative or additional therapeutic approaches need to be explored. Because of its restricted expression in normal human tissues (a small subset of activated lymphocytes),' the CD30 molecule expressed by ALCL cells can be regarded as an optimal target for immunotherapy with specific anti-CD30 monoclonal antibodies (MoAbs). 20 .21 Due to its high avidity for the CD30 antigen, the Ber-H2 MoAb" (IgG1 subclass with low affinity for the human Ig-Fc-receptor) has been recently selected for therapeutic purposes in patients with refractory Hodgkin's disease (HD),22.23 whose neoplastic components [Hodgkin's and Reed-Stemberg (R-S) cells] strongly express the CD30 antigen.
In a previous study, we provided immunohistologic evidence that the restricted in vitro reactivity of unmodified Ber-H2 with normal tissues is maintained in vivo and that optimal in vivo targeting of Hodgkin's and R-S cells can be achieved by injecting HD patients with low doses of Ber-H2 (15 mg to 40 mg)." However, none of our patients showed tumor regression in response to the infusion of the unmodified antibody.22 This prompted us to construct an anti-CD30 immunotoxin by linking the Ber-H2 MoAb to the powerful plant ribosome-inactivating protein saporin tumor transplantation. In contrast, injection of the IT at la?er stages of tumor growth (mice bearing subcutaneous tumors of 40-t o 60-mm3 volume), induced CR m only 6 of 21 (approximately 30%) mice and significantly delayed tumor growth rate (P < .01). This finding suggests that maximum effect of the anti-CD30 IT is observed when tumor cell burden is small. Persistent tumors from IT-treated mice consisted of CD30' cells, thus excluding the possibility that selection of CD30-negative mutant clones during IT therapy was responsible for resistance to treatment. We conclude that Ber-HPISOG IT is an effective agent against CD30+ ALCL growing in SCID mice, suggesting its possible role as adjuvant therapy in patients with CD30+ ALCL refractory to standard treatments. Based on the promising results of HD, the possibility of extending the use of Ber-H2/S06 to the treatment of refractory ALCL appears to be attractive. Therefore, we assessed in preclinical studies the antitumor activity of Ber-H2/S06 in vitro against the CD30+ ALCL-derived cell line JB6 and in vivo using our newly established severe combined immunodeficiency disease (SCID) mouse model of human xenografted CD30+ ALCL.28
MATERIALS AND METHODS

Cells
The JB6 cell line was established by in vitro culture of peripheral blood leukemic cells from a 12-year-old boy with advanced, treatment-resistant ALCL expressing a T-cell phenotype and the distinc-tive chromosome translocation. t(2;5) (p23;q35).?' Cells were maintained by serial passage in complete RPM1 1640 medium (GIBCOBiocult Ltd, Paisley, UK) supplemented with 15% (vol/vol) heatinactivated fetal bovine serum, penicillin (100 IU/mL), streptomicin (100 @g/mL), fungizone (0.25 pg/mL), and L-glutamine (2 mmoll L). Cell cultures were incubated at 37°C in a humidified 5% CO' atmosphere.
The HD-derived L428 and L540 cell lines were grown in a similar manner. The L540 cell line required 50 U/mL. of interleukin-2 (IL-2; Glaxo, Geneva, Switzerland) for optimal growth conditions.
Animals
Either male or female 4-to 6-week-old pathogen-free C.B-17 scidl scid mice were purchased from Taconic Farms Inc (Germantown, NY) and Charles River Italia Spa (Calco, Italy) and were maintained under sterile conditions in the animal facilities at the Joint Center for Radiatioq Therapy, New England Deaconess Hospital, Boston, MA, and at the University of Perugia, Perugia, Italy.
SCID/JB6 Mice
Development of human CD30' ALCL in SCID mice was originally obtained by intraperitoneal (IP) injection of lo8 JB6 cells into four animals; this resulted in a widespread tumor in one mouse. For the propagation of solid tumors, an abdominal mass was removed and minced in Hanks' balanced salt solution (HBSS) medium. Five to six small tissue fragments (2 to 3 mm in diameter) were implanted subcutaneously (SC) into the right flank of carrier mice with a trochar. The fragments produced palpable tumors in more than 90% of mice by day 7, and no variation in engrafment or in kinetics of growth was noted throughout the study. The subcutaneous tumors remained outside the abdominal wall fascia and did not metastasize. 
MoAbs
Mouse MoAbs specific for CD30 (Ber-H2)" and for the B-cell antigen CD22 (OM124)30 were used in this study. Both antibodies (mouse IgGl subclass) were purified from hybridoma culture supernatant by affinity-chromatography on protein A-Sepharose CL-4B, as previously described." The antibody preparation [greater than 95% pure as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)] was free from bacteria, fungi, and adventitious viruses. The limulus amebocyte lysate assay for endotoxin was negative.
S 0 6
The plant toxin S06, a single-chain (type I ) ribosome-inactivating proteid (RIP 1) of molecular weight 30,000,3' was purified from the seeds of Saponaria officinalis (provided by the Botanical Officinal Garden of Casola Valsenio, Ravenna, Italy) as described previously.'?
Ber-H2/S06 IT
The Ber-H2/S06 and OM124/S06 ITS were prepared under sterile conditions by linking S 0 6 to the purifieii Ber-H2 or OM124 with 2-iminothiolane and were separated from the unreacted components by gel filtration on a Sephacryl S-200 high resolution column, as previously de~cribed.?~
Reactivity of Ber-H2/S06 IT
Frozen sections from a variety of normal human tissues of lymphohematopoietic, epithelial, mesenchymal, or neuroectodermal origin were tested for their reactivity with Ber-H2/S06 IT. The ability of Ber-H2/S06 IT to bind CD30+ JB6 cells was assessed on both cytospin preparations from the JB6 cell line and on frozen sections from CD30' JB6 tumor samples in SCID mice. The immuno-alkaline phosphatase (APAAP) technique was used as detection system.'' Briefly, cytospins and frozen sections were incubated with the Ber-H2/S06 IT or the native Ber-H2 MoAb (positive control), followed by rabbit anti-mouse Ig (Dako, Glostrup, Denmark) and APAAP immune complexes. All steps were for 30 minutes with washes in 0.05 m o m Tris-buffered saline (TBS), pH 7.6. The alkaline phosphatase reaction was revealed by the new Fucsin substrate. 33 The endogenous alkaline phosphatase was blocked by adding levamisole to the substrate solution at the final concentration of 1 mm~liL.'~
Direct Cytotoxicity Assay
The toxicity of Ber-H2/S06 IT to JB6 cells was evaluated in vitro by a nonradioactive cell cytotoxicity assay (Promega Cell Titer 96; Promega Corp, Madison, WI), based on the cellular conversion of a tetrazolium salt into a blue formazan product that can be detected using an enzyme-linked immunosorbent assay (ELISA) plate reader. Cells, checked for viahlity and adjusted to a concentration of 4 X 10S/mL in complete RPM1 1640 medium, were distributed into triplicate wells of a 96-well microtiter plate in 50-pL volume (2 X lo4 per well), and 50 pL of Ber-H2/S06 IT solution was added to a final concentration ranging from 5 X lo-* molk to 5 X mol/L (as S06). Control samples were run with unconjugated Ber-H2 MoAb, S06 alone, unconjugated Ber-H2 plus S06, and with an anti-CD22/S06 conjugate as irrelevant IT. The CD30-negative Bcell line LCL was used as an irrelevant target for Ber-H2/S06. Plates were incubated for 24 hours at 37°C in a humidified 5% COz atmosphere, and then 15 pL of dye solution was added to culture wells for 4 hours, followed by an overnight incubation with 100 pL of a solubilizatiodstop solution. A570 was determined using an ELISA plate reader, and the percentage of reduction, compared with untreated control cultures, was used as assessment of the lulling. The in vitro toxicity of Ber-HUS06 IT was also tested in parallel from the inhibition of protein synthesis, as previously described (ICso = concentration of IT at which the 'H-leucine incorporation is inhibited by 50% relative to control culture).zh
In Vivo Antitumor Experiments
Prevention of tumor development. To evaluate the ability of Ber-H2/S06 in preventing tumor growth, IT therapy was started 24 hours after tumor transplantation. Mice were randomly divided into groups of six to seven, and the Ber-H2/S06 IT was injected IP under sterile conditions in a volume of 200 pL of phosphate-buffered saline (PBS) on days I , 3, and 5 after transplantation with a daily dose of 3.3 pg as S 0 6 (1 1.3 pg as Ber-H2/S06). The total dose administered (about I O pg as S06; 34 pg as Ber-H2/S06) corresponded to 50% of LDsO, as established Control mice received S 0 6 alone or the unconjugated MoAb in amounts equivalent to those used in the IT.
Treatment of established subcutaneous tumors. In further experiments, IT therapy was started IP when the tumor had grown SC to approximately 0.5 cm in diameter (day 5 after tumor implantation). On 3 consecutive days, mice received three IP injections of IT (1 1.3 pg per mouse per day in 0.2 mL PBS). The total dose of IT was 34 pg (ratio = 10 pg S06:24 pg Ber-H2). Mice injected with PBS, unconjugated Ber-H2 MoAb, or S 0 6 alone, at a dosage matching that in the IT, were used as controls.
Tumor diameters were recorded three times weekly by a caliper, and tumor volume was estimated, as described above.29 Experiments were terminated 30 days after the animals were transplanted to keep the tumor diameters below 2 cm. The antitumor effects of different treatments were compared by determining the tumor growth delay, which is the difference between the number of days necessary for tumors in each group to reach 500 m m 3 volume as compared with untreated mice.
Histologic and Immunohistologic Analysis of SCID Mice Tissues
To assess'possible toxic effects of the IT and changes in tumor phenotype, all animals that developed a tumor in spite of IT treatment were subjected to complete autopsy. Both the tumor and the apparently uninvolved tissues were removed, fixed in 10% neutral buffered formalin or B5, and processed for routine histology.
A portion of the tumor was also 
Establishment and Characterization of Subcultures From Tumor-Bearing Mice
Tumors growing in IT-treated mice were removed under sterile conditions, rinsed in complete RPM1 1640 medium, and finely minced with a scalpel. The tumor fragments were then incubated in complete medium in a 24-well plate for 24 hours and subsequently transferred to 25-mL Falcon tissue culture flasks. When the tumor cells had been reestablished as morphologically homogeneous sublines (usually about 7 to 10 days later),, cells were checked for antigen expression by immunocytochemical analysis.
RESULTS
Growth of JB6 in SCID Mice
When transplanted SC into SCID mice, JB6 cells induced the growth of solid tumors in greater than 95% of animals. Tumors reached the diameter of 0.5 cm on average by day 7 (range, 5 to 10 days). Tumor cells showed the typical morphologic features of ALCL, ie, irregular, often indented nuclear profiles with prominent nucleoli and abundant cytoplasm (Fig 1) . The neoplastic cells showed the activated T phenotype of the original JB6 cell line (CD2+, CD7+, PF1+, CD25+, CD30+, CD71+, CDw70'; Fig 2) . Cytogenetic analysis of tumor-derived cells showed the same chromosome abnormality t(2;5) (p23;q35) in all cells examined, confirming the human origin and clonality of the JB6 population.
Characteristics of Ber-H2/S06 IT
Both Ber-H2/S06 and OM-l24/S06 conjugates contained an average of 1.7 mol of S 0 6 per molar of antibody as estimated by the radioactive content and by the protein concentration determined from
The reactivity pattern of the Ber-HUS06 IT with normal'and pathologic human tissues, as well as with the JB6 cell line (Fig 3) , was identical to that expected for the native Ber-H2 in vitro." No reactivity of the Ber-H2/S06 IT was observed with cytospins prepared from a variety of CD30-negative human cell lines, as well as with frozeh sections from CD30-negative humah neoplasms.
In Vitro Cytotoxicity of Ber-H2/S06 IT
The toxicity of Ber-H2/S06 to JB6 cells was assessed by incubating the cells with increasing concentrations of ITS at 37°C for 24 hours. Direct comparison between 'H-leucine incorporation and tetrazolium conversion as methods to assay the cytotoxicity of Ber-H2/S06 indicated less than a 5% difference in ,the final results. The Ber-H2/S06 IT was highly toxic to JB6 cells and inhibited protein synthesis by 50% at concentrations (IC,) of 3.23 X 10"' m o m as S06 (Fig 4) . The effects of Ber-H2/S06 on W 6 as cqmpared with HD-derived cell lines L540 and L428 are summarized in Tables l and 2 . The cytotoxic effect was specific, as the IT prepared from an anti-CD22 (OM-124) antibody, which does not bind to JB6 cells, was up to 10,000 times less toxic (data not shown). S06, alone or mixed with the Ber-H2 MoAb (IC5o, 5 X mom), was more toxic than the irrelevant conjugate (IC5o. 5 X lo-@ mom). This finding is likely due to the fact that (1) S 0 6 loses some activity on conjugation, and (2) the conjugate is a larger molecule and presumably enters less easily into cells other than macrophages. The CD30-negative B-cell cell line LCL was resistant to both the conjugate and the Ber-H2.
In Vivo Antitumor Activity of Ber-H2/S06 IT
Prevention of tumor development. A 3-day treatment with nontoxic doses of Ber-H2/S06 IT inhibited the development of JB6 tumors in SCID mice when started 24 hours after transplantation of JB6 tumor. In particular, 23 of 24 untreated control mice developed palpable tumors by day 7 after transplant, whereas only 4 of 19 IT-treated mice developed a tumor that was detectable at day 22 (15 days .of delay as compared with untreated mice; Table 3 ). In contrast, neither unconjugated Ber-H2 nor the toxin alone decreased the incidence. of tumor engraftment or induced a delay in tumor growth. Mean time to palpable tumor was 7 2 1 days in control mice injected with anti-CD30 MoAb or S 0 6 alone. At day 22 after transplytation, the volume of the subcutaneous mass in the IT-treated mice was markedly smaller as compared with controls ( Table 3) .
The animals treated with Ber-H2/S06 and that had no signs of tumor growth after 40 days were either given a further subcutaneous implant of JB6 tumor fragments (six mice) or observed for durability of remission up to 100 days (all other mice). All six animals reimplanted with JB6 developed subcutaneous tumors that grew as fast as an agematched group of control animals. The IT-treated animals had, therefore, not developed detectable resistance to the tumor cells, suggesting that failures in tumor establishment were not due to an intrinsic mouse-related resistance. None of the animals observed up, to 100 days developed tumor.
Treatment of subcutaneous established tumor. We next determined whether treatment with Ber-H2/S06 IT or MoAb alone could induce complete remissions when administered at later stages of tumor growth. Mice reoeived three doses of Ber-H2/S06 IT on 3 consecutive days, starting when For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Fig 5) . The slight delay in tumor growth observed after administration of the plant toxin alone was not statistically significant ( P > S ) . After 2 months, there was no evidence of disease in 25% of IT-treated animals. Only one of the six responding mice had a relapse 15 days after the end of IT treatment, but the tumor regrowth rate was considerably slower than control growth rates.
Signs of acute IT-related toxicity during the first 7 to 14 days of the study included body weight loss (about 20% at day 5 from the end of therapy), slight transient thrombocytopenia, and increases in serum transaminases. There were no IT-related deaths. No tissue damage was seen at histologic examination of liver, spleen, kidney, lung, and heart per- formed on animals killed 60 to 100 days after IT administration. Treatment resistance was not due to selection of CD30-negative lymphoma cells, as demonstrated by immunohistologic evidence of the CD30 antigen on persistent tumors removed from IT-treated mice.
DISCUSSION
In this report, we provide clear evidence that the anti-CD30 IT Ber-H2/S06 was specifically and highly toxic to the human CD30' ALCL cell line JB6 in vitro and that it also had a potent antitumor effect against JB6 tumor-bearing SCID mice. In contrast, neither the MoAb nor the toxin component of the IT at equivalent concentration had any significant impact on either engraftment or growth rate of JB6 tumors in SCID mice, indicating that the whole IT rather than an antibody-mediated effect was responsible for the antitumor activity. These findings are in keeping with a previous report from our group that demonstrated an antitumor effect of Ber-H2/S06,23 but not of the native Ber-H2 antibody,** in patients with refractory HD.
Our SCID model offered the opportunity to test experimentally for the first time ,the response to IT of human CD30' ALCL bearing the typical (2; 5) chromosomal translocation. A comparison of the results presented in this report with previous studies on animals xenografted with HD-derived human cell line^^"^^ is difficult, as the studies differ markedly in terms of kind of tumor, target molecule, MoAb, and toxin moieties used. Local and disseminated HD has been induced in triple beige (B-, T-, and natural killer-cell deficient) and SCID'mice, respectively, by injection of the HD-derived human cell line L-540.37,39 In SCID mice, the L-540 tumors grow with a histologic pattern that resembles ALCL more than HD,39 but the neoplastic cells lack the t(2;5) chromosomal translocation typical of ALCL. Thus, our JB6 t(2;5)/SCID mice would appear a more appropriate model for the study of biology and response to IT treatment of human ALCL in suitable hosts. Notably, the breakpoint of the t(2;5) translocation has been recently cloned and shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein kinase gene, ALK, on chromosome 2q23." This discovery should provide a future genetic marker for monitoring minimal residual disease in our JB6/SCID model. Animal models of HD have been used to evaluate the antitumor activities of different ITS, including anti-CD30/ dgA,37,40 anti-CD30/S06 ( P L Tazzari, personal communication, April 1992), ar1ti-CD25/dgA,~~ anti-CD25/dgA, and anti-IRa~/dgA.~~ As compared with anti-CD30 ITS constructed with dgA, Ber-H2/S06 used in this study appears to be more powerfulz6 and safer to handle in' quantity and has longer serum half-life (about 20 hours)." ITS directed against the CD25 molecule have been reported to be active against disseminated HD in SCID mice.39 As JB6 cells strongly express the CD25 molecule; our model is also suitable for assessing the antitumor effect of these ITS. However, the present study was focused on CD30 as tumor target, because we believe that olinical use of anti-CD25 I T S might be hampered by at least two factors. First, unlike CD30, CD25 is expressed only on a percentage of neoplastic cells in about half of HD and ALCL cases; second, the CD25 molecule is more widely expressed than CD30. in normal human tissues. CD25 is usually found o n normal activated T cells and macrophages, including lung alveolar macrophages; the latter reactivity might result in increased risk of IT-related pulmonary vascular leak syndrome.
Notably, the efficacy of treatment in this study appeared to be related to tumor size. Ber-HYS06 IT was more effective in preventing the development of neoplastic masses when administered 24 hours after tiansplantation of ALCL cells (CR rate, 80%), as compared with treatment starting 5 days' postimplantation, when the mean tumor nodule diameter was 40 to 60 mm3 (CR rate, 30%). Similar results,were recently reported by Winkler et al, 39 who used anti-CD25 and anti-IRac/deglycosylated ricin A-chain ITS to treat disseminated human HD in SCID mice. These findings and those reported by other investigators using different survival models and ITs4'" strongly suggest that ITS exhert their maximum effect when tumor cell burden is small, probably reflecting the difficulty of these high-molecular-weight molecules penetrating into large neoplastic masses. This view is supported by the evidence that, in our model, targeting of JB6 cells in vivo by the native Ber-H2 MoAb correlated with the size of implanted tumor, with the most inadequate labeling being observed in animals bearing subcutaneous tumors more than 0.5 cm in diameter (B. Falini, personal communication, June 1994). In contrast, we did not find at immunocytochemistry any loss of CD30 antigen on both frozen sections from tumors growing in IT-treated mice and neoplastic cells recultivated from them. Thus, inability of the IT to reach the tumor target under certain circumstances rather than the emergence of mutant neoplastic clones with reduced or lack of ability to bind the Ber-H2 MoAb is likely to represent one of the most important mechanisms of resistance to treatment. These experimental findings have been recently validated by preliminary phase I clinical trials in leukemias and lymphomas. They seem to explain the relapses observed in IT-treated patients and strongly suggest that ITS directed against the CD30 m~l e c u l e , '~~~~. " as well as other lymphoid-associated antigens (eg, CD19 or CD22):5.46 are likely to be most effective when used for treating minimal residual disease in combination with other forms of therapy, such as conventional chemotherapy or autologous bone marrow tran~p1antation.J~ There are two additional reasons to propose such an approach: ( I ) ITS directed against CD30 as well as other target antigens are expected to kill tumor cells with a mechanism different from that of chemotherapy (eg, inhibition of protein synthesis) and, therefore, are expected to be effective against chemoresistant and/or resting residual neoplastic cells; and (2) chemotherapy-and IT-related toxicities are ndt overlapping.
In conclusion, the experimental results presented in this study suggest a potential role for the Ber-H2/S06 IT in the therapy of low-burden or minimal residual disease in selected categories of CD30' ALCL, as well as other lymphoma subtypes (centroblastic, immunoblastic, mediastinal large B-cell, large pleomorphic T-cell, adult T-cell lymphomalleukemia) that might express strongly the CD30 antigen in a variable percentage of In this regard, our JB6/SCID mouse model provides a unique opportunity to further optimize IT treatment strategies including scheduling and dosing and to explore new therapeutic modalities based on the use of anti-CD30 ITS in combination with anti-CD30 radiolabeled or chemotherapic agents."
